2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosis
1997
Bone marrow transplant nephropathy: a case report and review of the literature.
Cruz D, Perazella M, Mahnensmith R. Bone marrow transplant nephropathy: a case report and review of the literature. Journal Of The American Society Of Nephrology 1997, 8: 166-73. PMID: 9013462, DOI: 10.1681/asn.v81166.Peer-Reviewed Original ResearchConceptsBone marrow transplant nephropathyBone marrow transplantationRenal injuryTransplant nephropathyMarrow transplantationLate renal injuryEarly renal injuryHemolytic uremic syndromeVariety of causesNephrotoxic medicationsRenal failurePathologic featuresCase reportUremic syndromeLate effectsRadiation therapyRenal syndromeSyndromeNephropathySubsequent treatmentTransplantationInjuryMedicationsChemotherapyReview